CA3280578A1 - Crystalline dipeptides useful in the synthesis of elamipretide - Google Patents
Crystalline dipeptides useful in the synthesis of elamipretideInfo
- Publication number
- CA3280578A1 CA3280578A1 CA3280578A CA3280578A CA3280578A1 CA 3280578 A1 CA3280578 A1 CA 3280578A1 CA 3280578 A CA3280578 A CA 3280578A CA 3280578 A CA3280578 A CA 3280578A CA 3280578 A1 CA3280578 A1 CA 3280578A1
- Authority
- CA
- Canada
- Prior art keywords
- elamipretide
- crystalline
- synthesis
- dipeptides
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862651430P | 2018-04-02 | 2018-04-02 | |
| US62/651,430 | 2018-04-02 | ||
| CA3095869A CA3095869C (en) | 2018-04-02 | 2019-03-28 | CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095869A Division CA3095869C (en) | 2018-04-02 | 2019-03-28 | CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3280578A1 true CA3280578A1 (en) | 2025-10-30 |
Family
ID=68101313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3280578A Pending CA3280578A1 (en) | 2018-04-02 | 2019-03-28 | Crystalline dipeptides useful in the synthesis of elamipretide |
| CA3095869A Active CA3095869C (en) | 2018-04-02 | 2019-03-28 | CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095869A Active CA3095869C (en) | 2018-04-02 | 2019-03-28 | CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10975118B2 (https=) |
| EP (2) | EP4219523A3 (https=) |
| JP (2) | JP7350007B2 (https=) |
| KR (2) | KR20250010134A (https=) |
| CN (2) | CN112292388B (https=) |
| AU (1) | AU2019249121B2 (https=) |
| CA (2) | CA3280578A1 (https=) |
| DK (1) | DK3774844T3 (https=) |
| ES (1) | ES2941266T3 (https=) |
| FI (1) | FI3774844T3 (https=) |
| IL (2) | IL277718B2 (https=) |
| PT (1) | PT3774844T (https=) |
| WO (1) | WO2019195080A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3017359A1 (en) * | 2016-03-11 | 2017-09-14 | Scott M. Duncan | Crystalline salt forms |
| KR20250010134A (ko) | 2018-04-02 | 2025-01-20 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 엘라미프레티드의 합성에 유용한 결정질 디펩티드 |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4711166B2 (ja) * | 2004-08-03 | 2011-06-29 | 株式会社 液晶先端技術開発センター | 結晶化装置、および結晶化方法 |
| CA3022250A1 (en) * | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| CN108558969A (zh) * | 2014-03-28 | 2018-09-21 | 江苏天士力帝益药业有限公司 | 吡唑衍生物的多晶型物 |
| WO2016001042A1 (en) | 2014-06-30 | 2016-01-07 | Flamma S.P.A. | Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide |
| EP3265109B1 (en) * | 2015-03-06 | 2020-10-21 | Stealth BioTherapeutics Corp | Processes for preparing pharmaceutically relevant peptides |
| AU2016272089B2 (en) * | 2015-06-03 | 2021-02-18 | Triastek, Inc. | Dosage forms and use thereof |
| CA3017359A1 (en) * | 2016-03-11 | 2017-09-14 | Scott M. Duncan | Crystalline salt forms |
| EP3500286A4 (en) | 2016-08-16 | 2020-03-25 | Stealth BioTherapeutics Corp | N-CARBOXYANHYDRIDE-BASED SCALE SYNTHESIS OF ELAMIPRETID |
| US11034724B2 (en) * | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| KR20250010134A (ko) | 2018-04-02 | 2025-01-20 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 엘라미프레티드의 합성에 유용한 결정질 디펩티드 |
-
2019
- 2019-03-28 KR KR1020257000322A patent/KR20250010134A/ko active Pending
- 2019-03-28 EP EP23156906.2A patent/EP4219523A3/en active Pending
- 2019-03-28 PT PT197814320T patent/PT3774844T/pt unknown
- 2019-03-28 AU AU2019249121A patent/AU2019249121B2/en active Active
- 2019-03-28 US US16/485,369 patent/US10975118B2/en active Active
- 2019-03-28 ES ES19781432T patent/ES2941266T3/es active Active
- 2019-03-28 IL IL277718A patent/IL277718B2/en unknown
- 2019-03-28 DK DK19781432.0T patent/DK3774844T3/da active
- 2019-03-28 FI FIEP19781432.0T patent/FI3774844T3/fi active
- 2019-03-28 CA CA3280578A patent/CA3280578A1/en active Pending
- 2019-03-28 IL IL315355A patent/IL315355A/en unknown
- 2019-03-28 CA CA3095869A patent/CA3095869C/en active Active
- 2019-03-28 CN CN201980037029.8A patent/CN112292388B/zh active Active
- 2019-03-28 JP JP2020554100A patent/JP7350007B2/ja active Active
- 2019-03-28 KR KR1020207031595A patent/KR102753323B1/ko active Active
- 2019-03-28 EP EP19781432.0A patent/EP3774844B1/en active Active
- 2019-03-28 CN CN202410219985.0A patent/CN118206614A/zh active Pending
- 2019-03-28 WO PCT/US2019/024617 patent/WO2019195080A1/en not_active Ceased
-
2021
- 2021-04-07 US US17/224,353 patent/US11560404B2/en active Active
-
2022
- 2022-12-21 US US18/086,203 patent/US12018094B2/en active Active
-
2023
- 2023-09-12 JP JP2023147376A patent/JP7663642B2/ja active Active
-
2024
- 2024-05-15 US US18/665,100 patent/US20250122238A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3286688A1 (en) | Novel crystalline forms | |
| EP3628007A4 (en) | NEW SALTS AND CRYSTALS | |
| WO2016100732A3 (en) | Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives | |
| CA3275666A1 (en) | Crystalline forms of the nrtti compound 4’-ethynyl-2-fluoro-2’- deoxyadenosine | |
| IL277718A (en) | Crystalline dipeptides used in the synthesis of almiparatide | |
| PT3818059T (pt) | Intermediários na síntese de cefalosporinas substituídas em c3 | |
| IL282676B1 (en) | New dipeptide compounds and their uses | |
| EP3983423A4 (en) | SYNTHESIS OF 3-AZIDO-3-DEOXY-D-GALACTOPYRANOSE | |
| EP3689862A4 (en) | CRYSTALS | |
| AU2018903973A0 (en) | Polyacrylontrile synthesis | |
| HK40044019A (en) | Fasoracetam crystalline forms | |
| HK40016645A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| HK40071142A (en) | Compounds for use in synthesis of peptidomimetics | |
| HK40025364A (en) | Novel crystalline forms | |
| EP3634400A4 (en) | NEW CRYSTALLINE SHAPES | |
| HK40020441A (en) | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 | |
| HK40029662A (en) | Novel salts and crystals | |
| HK40025092A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| HK40022783A (en) | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof | |
| EP3651880A4 (en) | SUMMARY OF LIGHT CORE ELEMENTS | |
| HK40014545A (en) | Crystalline forms of (s)-afoxolaner | |
| AU2017903743A0 (en) | Synthesis of Lithium Titanate | |
| HK40011211A (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| EM34416660062S (de) | Uhrgläser | |
| EM34416660003S (bg) | Часовникарски кристали |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL Effective date: 20250721 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250926 |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250926 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250926 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250926 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20251003 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251020 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251020 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20251030 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251218 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |